BioMarin Pharmaceuticals BMRN Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's financing cash flow?
- BioMarin Pharmaceuticals (BMRN) reported financing cash flow of $813.17M in Q1 2026.
- How has BioMarin Pharmaceuticals's financing cash flow changed year-over-year?
- BioMarin Pharmaceuticals's financing cash flow increased by 2196.9% year-over-year, from -$38.78M to $813.17M.
- What does financing cash flow mean?
- The net cash flow resulting from changes in the company's debt and equity capital.
- How do you interpret financing cash flow?
- Positive values indicate net capital raising; negative values indicate debt repayment, share buybacks, or dividend payouts.
- How does financing cash flow compare across companies?
- Highly dependent on the company's lifecycle stage; growth companies often show positive inflows, while mature companies show outflows.